Link Silicon Valley
The fastest way to connect to the people, companies and capital of Silicon Valley
Free 30 Day Trial Account
Sign Up | Log In
Search
 
My Lists

Gemmus Pharma

409 Illinois Street, Suite 4004
San Francisco, CA 94158
USA
(415) 978-2151
Website Company Summary Management Team
Management

President/COO/Operations: William J Guilford
Finance: Jonathan Ross (4/30/2014)
Business Development: William K Holstein
Board

Outside board: (May no longer be on the board) Marc R Rubin (Titan Pharmaceuticals Executive Chairman) Christopher Dunn (Pulmonary and Critical Care Medicine physician) Larry Miller (Innovation Works Executive In Residence)
Company

Business description: Gemmus is a privately held biotechnology company focused on the development of innovative pharmaceutical products for the treatment of influenza and other viral infectious diseases. Using a novel, host-directed approach, we target the underlying cause of debilitating symptoms associated with influenza and 'influenza-like-illness' (ILI) by modulating the natural immune response to the disease. We are committed to developing “first-in-class, best-in-class” products that meet a major medical need. Gemmus Pharma was founded in 2007 to commercialize in-licensed technology from a major pharmaceutical company. Gemmus' lead candidate is a cardiovascular drug currently marketed in Asia that has been repurposed for use as a treatment for influenza. Gemmus has received support from the National Institute of Allergy and Infectious Disease (NIAID) and has completed Series A and B rounds totaling $4.75M from a syndicate of Angel Investors. The company has applied for and received an SBIR(NIH) and QTDP competitive grant. Gemmus' investigational new drug (IND) application for the treatment of influenza infections was accepted by the FDA in April 2015. Gemmus plans to start clinical trials in Q2 2015.
Capital

Rounds: 2
Recent Fundings: May 2014   Jun 2012
Capital raised: 5.1M
Last Round: 3.3M
Ownership: Private  
VCs include: Tech Coast Angels;  BlueTree Allied Angels;  Wilmington Investor Network;  Xandex Investments

Last Tweets


 

Last Mentions


Overview
Record updated: Feb 2017
Sector: Biotech
Year Founded: 2007
Headcount: 11-25
Rounds: 2
Recent Fundings: May 2014   Jun 2012
Capital Raised: 5.1M
Last Round: 3.3M
Ownership: Private